ClinicalTrials.gg
RecruitingNCT05919511THRIVEUpdated Oct 6, 2026

Observational Study for Patients at Risk for Chronic Graft-Versus-Host Disease

An observational study in cGVHD, sponsored by Incyte Corporation. Recruiting at 37 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-06.

Sponsored by Incyte Corporation · Observational

How we know

From the registry’s dates

  • Started Aug 2023; still recruiting 3 years 3 months later.
Updated Oct 6, 20265 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
1,500
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies in Bronchiolitis Obliterans Syndrome by Incyte Corporation — 4 open to participants now, 8 under way, 4 of them phase 3. Bronchiolitis Obliterans Syndrome · Incyte Corporation.

Started
2023
the only one that year
Observational
Only one
of the 12
Registered
5th of 12
by date

Among the 12 studies in Bronchiolitis Obliterans Syndrome by Incyte Corporation, this one is the only one that started in 2023, is the only observational one, and was the 5th registered.

Bronchiolitis Obliterans Syndrome

714 studies on the registry are indexed under Bronchiolitis Obliterans Syndrome; 128 are open to participants now.

Browse Bronchiolitis Obliterans Syndrome studies →

Open to participants now

4 of the 12 studies in Bronchiolitis Obliterans Syndrome by Incyte Corporation are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 100 Bronchiolitis Obliterans Syndrome studies recruiting now, 45 (45%) set no upper age limit and 45 (45%) stop at 75 or younger; 25 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Bronchiolitis Obliterans Syndrome by Incyte Corporation, or all of them as a file.
02

Study summary

The purpose of this prospective observational study is to collect data from participants who have recently had an allogenic Stem Cell Transplant(alloSCT) and are at risk of Chronic Graft Versus Host Disease(cGVHD)

03

Conditions studied

  • cGVHD

Keywords

  • chronic graft versus host disease
  • cGVHD
  • MA-GVHD-401
  • THRIVE
  • GVHD
  • chronic GVHD
  • allogenic stem cell transplant (alloSCT)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Participants greater than or equal to 18 years of age who have had Allogenic SCT 90 to 180 days prior to enrollment

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years inclusive at the time of signing the ICF
  • SCT 90 to 180 days prior to enrollment
  • Able to comprehend and willing to provide
  • Willing and able to complete participant-assessment questionnaires either alone or with minimal assistance from a caregiver and/or trained site personnel

Exclusion criteria

Exclusion Criteria:

  • There are no exclusion criteria for this study
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
1,500 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • At risk for GVHD

    Equal or Greater than 18 years old post alloSCT

    Other: Non-Interventional

Interventions

  • OtherNon-Interventional

    This is an observational study

06

What researchers measure

Primary outcomes

  1. Overall Burden of cGVHD diagnosis and severity

    Time frame: 36 months

Secondary outcomes

  1. To describe personal and healthcare resources associated with the management of cGVHD

    Time frame: 36 months

  2. To describe changes in the proteomic, cytologic and molecular profile in blood, serum and saliva cGVHD

    Time frame: Up to 36 months

07

Study locations

36 of 37 sites recruiting
08

References and documents

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2023 (actual). Primary completion is estimated for Oct 2027, 50 months after the start.

Of 57 observational studies under Bronchiolitis Obliterans Syndrome, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 62. This study's planned 50 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
May 5, 2023
First posted
Jun 26, 2023
StartActual
Aug 1, 2023
Primary completionEst.
Oct 15, 2027
CompletionEst.
Oct 15, 2027
Last update
Oct 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
5 sites added
Show 5 added (5 United States)
  • Colorado Blood Cancer Institute/Presbyterian St. Luke's · Denver, United States
  • Karmanos Cancer Institute · Detroit, United States
  • Tristar Centennial Blood & Marrow Transplant · Nashville, United States
  • Sarah Cannon Blood Cancer Center at St. Davids's South Austin Medical Center · Austin, United States
  • Methodist Hospital · San Antonio, United States
Oct 6, 2026
Show all 1 update
  1. Oct 6, 2026
    5 sites added
    Show 5 added (5 United States)
    • Colorado Blood Cancer Institute/Presbyterian St. Luke's · Denver, United States
    • Karmanos Cancer Institute · Detroit, United States
    • Tristar Centennial Blood & Marrow Transplant · Nashville, United States
    • Sarah Cannon Blood Cancer Center at St. Davids's South Austin Medical Center · Austin, United States
    • Methodist Hospital · San Antonio, United States
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05919511
Lead sponsor
Incyte Corporation
Responsible party
Sponsor
First posted
Jun 26, 2023
Start date
Aug 1, 2023
Primary completion
Oct 15, 2027 (estimated)
Completion
Oct 15, 2027 (estimated)
Last update
Oct 6, 2026

Study contacts

Incyte Corporation Call Center (US)
Contact
medinfo@incyte.com
1.855.463.3463
Incyte Corporation Call Center (ex-US)
Contact
eumedinfo@incyte.com
+800 00027423

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion